Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGSXCM-DW1
- Development stage
- Preclinical
- Lead developer
- PrimeGen Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Topical
01
Overview
PGSXCM-DW1 is a preclinical therapeutic candidate developed by PrimeGen Biotech for the treatment of dermal wounds. While specific molecular details are limited, the designation suggests it is likely derived from PrimeGen's proprietary stem cell platform, potentially utilizing stem cell-conditioned media (secretome) or a specific stem cell-derived product. PrimeGen Biotech specializes in the development of 'PrimeCells,' which are adult stem cells derived from germ cells. PGSXCM-DW1 is intended to leverage the regenerative and paracrine signaling properties of these cells to promote tissue repair, reduce inflammation, and accelerate the healing process in skin injuries.
Beyond the preview
Go deeper on PGSXCM-DW1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGSXCM-DW1.